智通财经APP讯,百利天恒(688506.SH)发布公告,公司自主研发的创新生物药注射用BL-M07D1(HER2ADC)单药用于HER2低表达复发或转移性乳腺癌的III期临床试验已于近日完成首例受试者入组。
BL-M07D1是一种靶向HER2的创新型ADC,具有同类最佳(Best-in-class)潜力,已在临床试验中展示出显著的抗肿瘤功效。近日,BL-M07D1单药治疗HER2低表达复发或转移性乳腺癌的临床研究已进入III期临床试验阶段并完成首例受试者入组。
截至目前,BL-M07D1正在国内外开展12项临床试验,包括3个III期、3个II期、3个I/II期及3个I期临床试验,覆盖二线及以上HER2阳性乳腺癌、HER2阳性乳腺癌术后辅助、HER2阳性乳腺癌新辅助治疗和HER2低表达乳腺癌,以及肺癌、消化道肿瘤、泌尿系统肿瘤和妇科肿瘤等多项适应症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.